Publication Name	World Journal of Hepatology
Manuscript ID	28817
Country	Greece

Received	2016-07-18 10:04
Peer-Review Started	2016-07-18 20:45
To Make the First Decision	2016-08-26 08:16
Return for Revision	2016-08-29 17:00
Revised	2016-10-14 05:58
Second Decision	2016-11-10 14:25
Accepted by Journal Editor-in-Chief	2016-11-11 14:13
Accepted by Company Editor-in-Chief	2016-11-22 15:26
Articles in Press	2016-11-22 15:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-01-03 08:54
Publish the Manuscript Online	2017-01-16 10:39

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Systemic treatment for hepatocellular carcinoma: Still unmet expectations
Manuscript Source	Invited Manuscript
All Author List	Dimitrios N Samonakis and Elias A Kouroumalis
Funding Agency and Grant Number
Corresponding Author	Dr. Dimitrios N Samonakis, Department of Gastroenterology and Hepatology, University Hospital of Hera­klion, Heraklion, 71110 Crete, Greece. dsamonakis@gmail.com
Key Words	Systemic; Chemotherapy; Hepatocellular carcinoma; Prognosis
Core Tip	The complete failure of chemotherapy in previous years gradually shifted hepatocellular car-cinoma (HCC) treatment to the molecular targeted therapies. The initial-albeit limited - effectiveness of the currently approved systemic therapy, sorafenib, is due to the successful combination of targeting cancer cells and their microenvironment. Trials on drugs other than sorafenib, alone or in combination with drugs or transcatheter arterial chemoembolization were dis-appointing. Recently, genomic based analyses in HCC patients have proposed subclasses, based on molecular characteristics and a proliferative or non-proliferative genotypes. Combined targeted therapies, driven by specific molecular signatures for treatment selection and monitoring, potentially with immunotherapy, could be a future personalized approach.
Publish Date	2017-01-16 10:39
Citation	Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol 2017; 9(2): 80-90
URL	http://www.wjgnet.com/1948-5182/full/v9/i2/80.htm
DOI	http://dx.doi.org/10.4254/wjh.v9.i2.80

Full Article (PDF)	WJH-9-80.pdf
Full Article (Word)	WJH-9-80.doc
Manuscript File	28817-Review.docx
Answering Reviewers	28817-Answering reviewers.pdf
Audio Core Tip	28817-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	28817-Conflict-of-interest statement.pdf
Copyright License Agreement	28817-Copyright assignment.pdf
Peer-review Report	28817-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	28817-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	28817-Scientific misconduct check.pdf
Scientific Editor Work List	28817-Scientific editor work list.pdf